(Q54496952)

English

Norfloxacin (MK-0366, AM-715): In vitro activity and cross-resistance with other organic acids including quality control limits for disk diffusion testing

scientific article published on June 1, 1983

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/6232084

Norfloxacin (MK-0366, AM-715): In vitro activity and cross-resistance with other organic acids including quality control limits for disk diffusion testing (English)

1 reference

10.1016/0732-8893(83)90047-0

https://api.crossref.org/works/10.1016/0732-8893(83)90047-0

2 September 2023

quality control

0 references

1

object named as

Jones RN

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/6232084

Arthur L. Barry

2

object named as

Barry AL

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/6232084

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=6232084

2 September 2023

publication date

1 June 1983

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/6232084

full work available at URL

https://api.elsevier.com/content/article/PII:0732889383900470?httpAccept=text/xml

1 reference

10.1016/0732-8893(83)90047-0

https://api.crossref.org/works/10.1016/0732-8893(83)90047-0

2 September 2023

https://api.elsevier.com/content/article/PII:0732889383900470?httpAccept=text/plain

1 reference

10.1016/0732-8893(83)90047-0

https://api.crossref.org/works/10.1016/0732-8893(83)90047-0

2 September 2023

Diagnostic Microbiology and Infectious Disease

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/6232084

1

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/6232084

2

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/6232084

165-172

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/6232084

Sch 29482, a new oral penem: comparative in-vitro activity, beta-lactamase stability and inhibition

1

1 reference

10.1016/0732-8893(83)90047-0

https://api.crossref.org/works/10.1016/0732-8893(83)90047-0

2 September 2023

Apparent absence of transferable resistance to nalidixic acid in pathogenic Gram-negative bacteria

2

1 reference

10.1016/0732-8893(83)90047-0

https://api.crossref.org/works/10.1016/0732-8893(83)90047-0

2 September 2023

Multiple antibiotic resistance and capsular types of gentamicin-resistant Klebsiella aerogenes.

3

1 reference

10.1016/0732-8893(83)90047-0

https://api.crossref.org/works/10.1016/0732-8893(83)90047-0

2 September 2023

Emergence of resistant organisms as a function of dose in oxolinic acid therapy

4

1 reference

10.1016/0732-8893(83)90047-0

https://api.crossref.org/works/10.1016/0732-8893(83)90047-0

2 September 2023

Nalidixic Acid: an Antibacterial Paradox

5

1 reference

10.1016/0732-8893(83)90047-0

https://api.crossref.org/works/10.1016/0732-8893(83)90047-0

2 September 2023

In vitro activity of MK-0366 against clinical urinary pathogens including gentamicin-resistant Pseudomonas aeruginosa

6

1 reference

10.1016/0732-8893(83)90047-0

https://api.crossref.org/works/10.1016/0732-8893(83)90047-0

2 September 2023

Comparison of the antibacterial activity of norfloxacin (MK 0366, AM 715), a new organic acid, with that of other orally absorbed chemotherapeutic agents

7

1 reference

10.1016/0732-8893(83)90047-0

https://api.crossref.org/works/10.1016/0732-8893(83)90047-0

2 September 2023

Quality control limits for ampicillin, carbenicillin, mezlocillin, and piperacillin disk diffusion susceptibility tests: a collaborative study.

8

1 reference

10.1016/0732-8893(83)90047-0

https://api.crossref.org/works/10.1016/0732-8893(83)90047-0

2 September 2023

Drug therapy reviews: nalidixic acid

9

1 reference

10.1016/0732-8893(83)90047-0

https://api.crossref.org/works/10.1016/0732-8893(83)90047-0

2 September 2023

Comparative activities of AM-715 and pipemidic and nalidixic acids against experimentally induced systemic and urinary tract infections

10

1 reference

10.1016/0732-8893(83)90047-0

https://api.crossref.org/works/10.1016/0732-8893(83)90047-0

2 September 2023

In vitro antibacterial activity of AM-715, a new nalidixic acid analog

11

1 reference

10.1016/0732-8893(83)90047-0

https://api.crossref.org/works/10.1016/0732-8893(83)90047-0

2 September 2023

In vitro antimicrobial activity of cinoxacin against 2,968 clinical bacterial isolates

12

1 reference

10.1016/0732-8893(83)90047-0

https://api.crossref.org/works/10.1016/0732-8893(83)90047-0

2 September 2023

In vitro antimicrobial activity evaluation of cefodizime (HR221), a new semisynthetic cephalosporin

13

1 reference

10.1016/0732-8893(83)90047-0

https://api.crossref.org/works/10.1016/0732-8893(83)90047-0

2 September 2023

Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests

14

1 reference

10.1016/0732-8893(83)90047-0

https://api.crossref.org/works/10.1016/0732-8893(83)90047-0

2 September 2023

Comparative in vitro activity of Mk-0366 and other selected oral antimicrobial agents against Neisseria gonorrhoeae

15

1 reference

10.1016/0732-8893(83)90047-0

https://api.crossref.org/works/10.1016/0732-8893(83)90047-0

2 September 2023

Comparative in vitro activity of norfloxacin (MK-0366) and ten other oral antimicrobial agents against urinary bacterial isolates

16

1 reference

10.1016/0732-8893(83)90047-0

https://api.crossref.org/works/10.1016/0732-8893(83)90047-0

2 September 2023

In vitro antibacterial activity of norfloxacin (MK-0366).

17

1 reference

10.1016/0732-8893(83)90047-0

https://api.crossref.org/works/10.1016/0732-8893(83)90047-0

2 September 2023

A Critical Evaluation of Nalidixic Acid in Urinary-Tract Infections

21

1 reference

10.1016/0732-8893(83)90047-0

https://api.crossref.org/works/10.1016/0732-8893(83)90047-0

2 September 2023

Tentative interpretive standards for disk diffusion susceptibility testing with norfloxacin (MK-0366, AM-715)

22

1 reference

10.1016/0732-8893(83)90047-0

https://api.crossref.org/works/10.1016/0732-8893(83)90047-0

2 September 2023

Resistance to nalidixic acid. A misconception due to underdosage.

23

1 reference

10.1016/0732-8893(83)90047-0

https://api.crossref.org/works/10.1016/0732-8893(83)90047-0

2 September 2023

Identifiers

10.1016/0732-8893(83)90047-0

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/6232084

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/6232084

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54496952&oldid=1966939216"